Pfizer will use Ichor Medical Systems devices for cancer vaccine development

Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's ($PFE) preclinical cancer vaccine research efforts. Neither side is disclosing financial details, but San Diego-based Ichor gets an upfront payment plus milestone and royalty cash based on potential future sales. Both sides will share some development expenses. Ichor is known for its TriGrid Delivery System, an integrated and fully automated device for electroporation-mediated DNA administration in humans. The technology enables the delivery of DNA drugs and vaccines for diseases such as cancer, malaria, hepatitis B and HIV, Ichor said. Release

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.